---
title: "CSPC PHARMA's new drug SYH2066 has been approved to conduct clinical trials"
description: "CSPC PHARMA announced that its main research and development chemical Class 1 new drug SYH2066 tablets have been approved by the National Medical Products Administration of China to conduct clinical t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257245297.md"
published_at: "2025-09-14T09:49:51.000Z"
---

# CSPC PHARMA's new drug SYH2066 has been approved to conduct clinical trials

> CSPC PHARMA announced that its main research and development chemical Class 1 new drug SYH2066 tablets have been approved by the National Medical Products Administration of China to conduct clinical trials in China. The approved indication is for the treatment of respiratory infections caused by respiratory syncytial virus

CSPC PHARMA (01093.HK) announced that its main research and development chemical class 1 new drug SYH2066 tablets have been approved by the National Medical Products Administration of China to conduct clinical trials in China. The approved indication is for the treatment of respiratory infections caused by respiratory syncytial virus

### Related Stocks

- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/en/news/276113491.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/en/news/275851575.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.